MYGN (Myriad Genetics) רווח נקי למניה (EPS TTM)

This daily price chart of the 12-month EPS trend provided by GURU.Markets demonstrates the profitability dynamics of Myriad Genetics, Inc. (MYGN), where -1.37 reflects the metric's most recent value. Myriad Genetics, Inc. (MYGN) leads the genetic testing sector, effectively monetizing its database. The strategy is based on expansion into pharmacogenomics and cost reduction. Environmental policy relies on the safe disposal of biomaterials and the digitalization of document workflows.

For molecular diagnostics leader Myriad Genetics, Inc. (MYGN), this indicator reflects the efficiency of monetizing unique genomic arrays and the protection of its market niche through the lens of actual profit. The trend of the rolling trailing twelve-month earnings per share aggregates the net result of the last four quarters, allowing investors to assess the fundamental value of the stock without distortions from short-term reporting fluctuations.